BAT to Launch Glo Hyper Air WINNER Edition, Priced at 40,000 Korean Won

BAT by 2FIRSTS.ai
Jan.08.2024
BAT to Launch Glo Hyper Air WINNER Edition, Priced at 40,000 Korean Won
BAT Korea will release the Glo Hyper Air WINNER Edition, featuring artwork by selected artists.

According to a report by the South Korean media outlet Etoday on January 8th, British American Tobacco Korea is planning to launch the Glo Hyper Air WINNER edition.

 

Last year, British American Tobacco collaborated with the visual artist platform Pixpills in South Korea to host an art competition. Subsequently, five artworks were selected as the final winners through consumer online voting.

 

The Glo Hyper Air WINNER edition package includes one Glo Hyper Air device, a design skin featuring artwork by an artist, and a paper bag with the same artwork. The design skin can be easily attached to the device using stickers, while the product packaging also showcases the artist's work, enhancing its collectible value.

 

The Glo Hyper Air Winner Edition will be sold at 40,000 Korean Won (30 USD). It will be available in limited quantity on the Glo website, "Discover Glo," Kakao Store, Naver Smart Store, and other platforms.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Ireland to Impose EU’s Highest Tax on Vape E-Liquids: €0.50 per ml, Effective Nov. 1
Ireland to Impose EU’s Highest Tax on Vape E-Liquids: €0.50 per ml, Effective Nov. 1
From Nov. 1, Ireland will levy €0.50/ml on all e-liquids and tighten rules—including a disposable ban; advocates warn this could hinder quitting amid a missed 2025 target.
Oct.21 by 2FIRSTS.ai
Philip Morris International to Boost Investment in the Philippines, Aiming to Make It a Smoke-Free Products Export Hub
Philip Morris International to Boost Investment in the Philippines, Aiming to Make It a Smoke-Free Products Export Hub
PMI to make the Philippines a smoke-free export hub, citing strong regulation; upgrading local plants, expanding affordable supply; $14bn invested globally.
Oct.11 by 2FIRSTS.ai
Product | SKE Launches Disposable V-BOT, Claiming U.S. Manufacturing and Domestic Blending & Filling
Product | SKE Launches Disposable V-BOT, Claiming U.S. Manufacturing and Domestic Blending & Filling
SKE has launched the V-BOT disposable e-cigarette. The company’s website highlights that the device is “Made in the USA,” with blending and filling also completed domestically. The V-BOT features dual power modes (Eco/Boost), an 800 mAh rechargeable battery, and is advertised as delivering up to 40,000 puffs.
Nov.07 by 2FIRSTS.ai
Saratov Governor Supports Russian Nationwide Ban on E-Cigarette Sales
Saratov Governor Supports Russian Nationwide Ban on E-Cigarette Sales
Governor of Saratov Oblast, announced on his official Telegram channel that he fully supports a nationwide ban on the sale of e-cigarettes. Busargin noted that while restrictions on such products have long been in place, enforcement remains weak and health experts continue to warn of the risks posed to children. He stressed that economic interests must not outweigh public health and said Saratov is ready to enforce a ban once regional powers are granted.
Nov.17 by 2FIRSTS.ai
PMI Launches New ZYN Nicotine Pouch in the Philippines, Available Simultaneously at IQOS Stores and on the Official Website
PMI Launches New ZYN Nicotine Pouch in the Philippines, Available Simultaneously at IQOS Stores and on the Official Website
PMI’s Philippine affiliate, PMFTC, has launched the new ZYN Bright Green 1.5 mg nicotine pouch in Manila with refreshed packaging, calling it the latest step in the company’s “smoke-free” transition initiated in 2016. The product will be available starting in November at IQOS stores across Metro Manila and on the official website.
Nov.10 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai